Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Urologic Neoplasms 4Ureteral Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Urethral Neoplasms 2Metastatic Urothelial Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Peripheral Nervous System Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Male Urogenital Diseases 1Head and Neck Neoplasms 1Female Urogenital Diseases 1Esophageal Neoplasms 1Carcinoma in Situ 1Advanced Solid Tumor 1

Interventions

sagopilone 1pembrolizumab 1nabilone 1eribulin 1enfortumab vedotin 1allantoicase 1Prednisolone 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Lenalidomide 1Exercise 1Epoetin Alfa 1BID protein, human 1Acetylcarnitine 14-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peripheral Nervous System Diseases × enfortumab vedotin × Clear all
NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡